RBC Capital raises Ultragenyx price target to $40

0 min read Updated on 08 Jul 2026, 01:19 AM

Reviewed by

Radhika SScanX News Team

AI Summary

RBC Capital analyst Luca Issi maintained an Outperform rating on Ultragenyx Pharmaceutical and raised the price target to $40 from $35, signaling a positive outlook for the NASDAQ-listed stock.

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Luca Issi has maintained an Outperform rating on Ultragenyx Pharmaceutical and raised the price target to $40 from $35. The adjustment reflects a revised valuation outlook for the NASDAQ-listed company.

Rating and Target Details

The research note reinforces a positive stance on Ultragenyx Pharmaceutical, trading under the ticker RARE. The new price target of $40 represents an increase over the prior target of $35.

Metric	Value
Rating	Outperform
Previous Price Target	$35
New Price Target	$40

What specific factors drove the revised valuation outlook for Ultragenyx?

How might this rating upgrade influence investor sentiment towards the biotech sector?

What upcoming clinical milestones could further impact Ultragenyx's stock performance?

Read Next Article

Ultragenyx grants 44,409 RSUs to new hires under Nasdaq rule

0 min read Updated on 20 Jun 2026, 02:04 AM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The awards, approved by the compensation committee, vest over four years with 25% vesting annually starting from the grant date of June 16, 2026.

*this image is generated using AI for illustrative purposes only.

Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units of its common stock to 15 newly hired non-executive officers as an inducement material to their employment. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan. The grant date was June 16, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date. Vesting is subject to the employee being continuously employed by the company as of such vesting dates.

Grant Details

Detail	Information
Total RSUs Granted	44,409
Recipients	15 newly hired non-executive officers
Grant Date	June 16, 2026
Vesting Schedule	25% annually over four years
Governing Rule	Nasdaq Listing Rule 5635(c)(4)

Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases. The company’s strategy is predicated upon time- and cost-efficient drug development to deliver safe and effective therapies to patients with high unmet medical needs.

What specific roles or expertise do these 15 new hires bring to Ultragenyx's pipeline?

How will the dilution from these RSUs impact existing shareholders over the next four years?

Does this hiring surge indicate an acceleration in clinical trials or expansion into new therapeutic areas?